首页> 美国卫生研究院文献>Science Advances >Computational integration of nanoscale physical biomarkers and cognitive assessments for Alzheimer’s disease diagnosis and prognosis
【2h】

Computational integration of nanoscale physical biomarkers and cognitive assessments for Alzheimer’s disease diagnosis and prognosis

机译:纳米级物理生物标记物和认知评估的计算集成用于阿尔茨海默氏病的诊断和预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

With the increasing prevalence of Alzheimer’s disease (AD), significant efforts have been directed toward developing novel diagnostics and biomarkers that can enhance AD detection and management. AD affects the cognition, behavior, function, and physiology of patients through mechanisms that are still being elucidated. Current AD diagnosis is contingent on evaluating which symptoms and signs a patient does or does not display. Concerns have been raised that AD diagnosis may be affected by how those measurements are analyzed. Unbiased means of diagnosing AD using computational algorithms that integrate multidisciplinary inputs, ranging from nanoscale biomarkers to cognitive assessments, and integrating both biochemical and physical changes may provide solutions to these limitations due to lack of understanding for the dynamic progress of the disease coupled with multiple symptoms in multiscale. We show that nanoscale physical properties of protein aggregates from the cerebral spinal fluid and blood of patients are altered during AD pathogenesis and that these properties can be used as a new class of “physical biomarkers.” Using a computational algorithm, developed to integrate these biomarkers and cognitive assessments, we demonstrate an approach to impartially diagnose AD and predict its progression. Real-time diagnostic updates of progression could be made on the basis of the changes in the physical biomarkers and the cognitive assessment scores of patients over time. Additionally, the Nyquist-Shannon sampling theorem was used to determine the minimum number of necessary patient checkups to effectively predict disease progression. This integrated computational approach can generate patient-specific, personalized signatures for AD diagnosis and prognosis.
机译:随着阿尔茨海默氏病(AD)的患病率不断提高,人们已大力致力于开发新型的诊断和生物标记物,以增强AD的检测和管理。 AD通过尚不清楚的机制影响患者的认知,行为,功能和生理。当前的AD诊断取决于评估患者显示或不显示哪些症状和体征。有人担心,AD分析可能会影响到AD诊断。使用集成了多学科输入(从纳米级生物标志物到认知评估)的计算算法,并整合生化和物理变化的计算算法来诊断AD的无偏方法,可能由于缺乏对疾病动态进展以及多种症状的了解而为这些局限性提供了解决方案在多尺度上。我们显示,AD发病机理中,患者脑脊髓液和血液中蛋白质聚集体的纳米级物理特性发生了变化,这些特性可以用作一类新的“物理生物标记物”。使用开发的算法来集成这些生物标志物和认知评估,我们演示了一种公正诊断AD并预测其进展的方法。可以基于身体生物标志物的变化以及患者随时间的认知评估得分来进行进展的实时诊断更新。另外,奈奎斯特-香农采样定理用于确定必要的患者检查的最小次数,以有效地预测疾病的进展。这种集成的计算方法可以为AD诊断和预后生成针对患者的个性化签名。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号